Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50523
Name adult T-cell leukemia/lymphoma
Definition A T-cell acute leukemia that results_in abnormal increase of lymphocytes, derives_from T-cells, has_material_basis_in Human T-lymphotropic virus 1 (HTLV-1), which is transmitted_by sexual contact, transmitted_by contaminated needles used by intravenous-drug users, and transmitted_by breast feeding. The infection results_in_formation_of skin lesions.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia adult T-cell leukemia/lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS G13V 3144 adult T-cell leukemia/lymphoma sensitive detail...
NRAS G13D 3144 adult T-cell leukemia/lymphoma sensitive detail...
FBXW7 positive JQ1 adult T-cell leukemia/lymphoma predicted - sensitive detail...
FBXW7 W425R JQ1 adult T-cell leukemia/lymphoma resistant detail...
FBXW7 W425R Birabresib adult T-cell leukemia/lymphoma resistant detail...
FBXW7 S462P JQ1 adult T-cell leukemia/lymphoma resistant detail...
FBXW7 S462P Birabresib adult T-cell leukemia/lymphoma resistant detail...
FBXW7 H468R JQ1 adult T-cell leukemia/lymphoma resistant detail...
FBXW7 H468R Birabresib adult T-cell leukemia/lymphoma resistant detail...
FBXW7 S462P JQ1 + PLX8394 adult T-cell leukemia/lymphoma sensitive detail...
FBXW7 S462P JQ1 + Ulixertinib adult T-cell leukemia/lymphoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01712659 Phase II Ruxolitinib Ruxolitinib for Adult T-Cell Leukemia Terminated USA 0
NCT02580552 Phase I MRG-106 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Completed USA 0
NCT02588651 Phase II Brentuximab vedotin A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Recruiting USA 0
NCT02631746 Phase II Nivolumab Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Completed USA 0
NCT02689453 Phase I Alemtuzumab + rhIL-15 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Completed USA 0
NCT02732275 Phase I DS-3201b DS-3201b in Participants With Lymphomas Active, not recruiting USA 1
NCT02737046 Phase II Interferon alpha-2b Peginterferon alfa-2b Belinostat + Zidovudine Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting USA 0
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Terminated USA 0
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT03264131 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma Active, not recruiting USA 0
NCT03829540 Phase I CD4CAR CD4CAR for CD4+ Leukemia and Lymphoma Recruiting USA 0
NCT04185220 Phase I Mogamulizumab + rhIL-15 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Completed USA 0
NCT04283097 Phase I KPG-818 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Recruiting USA 0
NCT04334174 Phase II Brentuximab vedotin Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T) Withdrawn USA 0
NCT04569032 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Active, not recruiting USA | ITA | GBR | FRA | ESP 1
NCT04639843 Phase I Azacitidine + Doxorubicin + Duvelisib + Romidepsin Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma Withdrawn USA 0
NCT04703192 Phase II DS-3201b Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT04747236 Phase II Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) Recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04848064 Phase I Cyclophosphamide + Fludarabine Mogamulizumab Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Recruiting USA 0
NCT04984837 Phase II Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin Study of Lacutamab in Peripheral T-cell Lymphoma Recruiting FRA | ESP | DEU | BEL 0
NCT05010005 Phase I Duvelisib + Ruxolitinib A Study of Ruxolitinib and Duvelisib in People With Lymphoma Active, not recruiting USA 0
NCT05065866 Phase I Azacitidine + Duvelisib Duvelisib in Combination With CC-486 in Lymphoid Malignancy Active, not recruiting USA 0
NCT05371054 Phase Ib/II Prednisone + Venetoclax + VIP152 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Recruiting USA 0
NCT05377827 Phase I WU-CART-007 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Recruiting USA 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT05983965 Phase I Tazemetostat Acalabrutinib + Tazemetostat Study of Tazemetostat in Lymphoid Malignancies Not yet recruiting USA 0